A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers

Recruiting

• Conditions: Hepatocholangiocarcinoma; Hepatic Epithelioid Hemangioendothelioma; Hepatoblastoma; Fibrolamellar Carcinoma; Hepatic Neuroendocrine Carcinoma; Hepatic Cystadenoma; Hepatic Leiomyosarcomas; Hepatic Angiosarcomas; Hepatic Carcinosarcomas; Cholangiocarcinoma

• Registration Number: NCT06541652
• Lead Sponsor: Federation Francophone de Cancerologie Digestive

Brief Summary

The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences. This retrospective cohort will be the backbone of future translational studies aimed at identifying new molecular, histological, circulating and radiological tumor biomarkers, potentially useful at every stage of diagnosis and prognostic or theranostic evaluation.

Detailed Description

The aim is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences.

Study Timeline

• Study Start: 2024-03-26
• Study First Submitted: 2024-07-15
• Study First Submitted QC: 2024-08-02
• Study First Posted: 2024-08-07
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-12
• Last Update Posted: 2025-02-14
• Primary Completion: 2026-02
• Study Completion: 2031-02

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• 18 years of age or older,
• with histologically proven hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma or hepatic angiosarcoma
• diagnosed after January 01, 2018 living or deceased at the time of registration in the cohort
• for living patients who have not objected to the research: (note of non-objection to be attached° agreeing to participate in ancillary studies must sign the biological consent form for participation in biological studies.

Exclusion Criteria

• without social security
• No access to tumor block

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Description of the clinical, histological and radiological characteristics of various rare primary liver cancers	up to 5 years from the date of diagnosis	Description of the clinical, histological and radiological characteristics of various rare primary liver cancers

Secondary Outcome Measures

Name	Time	Method
Recurrence-free survival (for non-metastatic patients)	up to 5 years from diagnosis	Time interval between the date of disease diagnosis and the date of locoregional and/or metastatic recurrence or death (all causes). Patients alive and without recurrence will be censored at the date of last news
Progression-free survival (for metastatic patients)	up to 5 years from diagnosis	Time interval between the date of diagnosis of the disease and the date of radiological and/or clinical progression or death (all causes). Patients alive and progression-free will be censored at the date of last news.
Overall survival	up to 5 years from diagnosis	Time interval between the date of diagnosis of the disease and the date of death (from all causes). Living patients will be censored at the date of last news.

Trial Locations

Locations (40)

CHU Amiens picardie; 🇫🇷 Amiens, France

Chu Angers; 🇫🇷 Angers, France

Ch - Centresimone Veil de Beauvais; 🇫🇷 Beauvais, France

Chu Jean Minjoz; 🇫🇷 Besançon, France

Ch Bethune Beuvry; 🇫🇷 Bethune, France

Avicenne; 🇫🇷 Bobigny, France

Cote de Nacre; 🇫🇷 Caen, France

Chu de Clichy Hopital Beaujon; 🇫🇷 Clichy, France

Centre Hospitalier Universitaire Henri Mondor; 🇫🇷 Creteil, France

CHU; 🇫🇷 Dijon, France

Chu Grenobles Alpes; 🇫🇷 La Tronche, France

Centre Hospital Universitaire de lille; 🇫🇷 Lille, France

Longjumeau Ch; 🇫🇷 Longjumeau, France

Ch Edouard Herriot; 🇫🇷 Lyon, France

Centre Léon Berard; 🇫🇷 Lyon, France

Clinique de La Sauvegarde; 🇫🇷 Lyon, France

La Clinique de La Sauvegarde; 🇫🇷 Lyon, France

Chu Edouard Herriot; 🇫🇷 Lyon, France

Chu La Croix Rousse; 🇫🇷 Lyon, France

Lyon Cac Leon Berard; 🇫🇷 Lyon, France

Lyon La Croix Rousse; 🇫🇷 Lyon, France

Hopital Saint Joseph; 🇫🇷 Marseille, France

Chu de La Timone; 🇫🇷 Marseille, France

CHR - Metz Thionville Hopital de Mercy; 🇫🇷 Metz, France

Chu de Paris Saint Antoine; 🇫🇷 Paris, France

AP - HP - Pitié Salpêtrière; 🇫🇷 Paris, France

PAU CH; 🇫🇷 Pau, France

Centre Hospitalier de Perpignan; 🇫🇷 Perpignan, France

Hopital Haut Leveque; 🇫🇷 Pessac, France

Chu de Poitiers; 🇫🇷 Poitiers, France

CH - Annecy Genevois; 🇫🇷 Pringy, France

Chu Robert Debre; 🇫🇷 Reims, France

CAC - Eugène Marquis; 🇫🇷 Rennes, France

Ico Site Rene Gauducheau; 🇫🇷 Saint-Herblain, France

Groupe Hospitalier Rance Emeraude; 🇫🇷 Saint-Malo, France

Hopital Nord Chu Saint Etienne; 🇫🇷 Saint-Priest-en-Jarez, France

Chu Rangueil; 🇫🇷 Toulouse, France

Chru de Tours; 🇫🇷 Tours, France

Chu Paul Brousse; 🇫🇷 Villejuif, France

Gustave Roussy; 🇫🇷 Villejuif, France